Summarized by Masters of Longevity from Longevity Technology.
Blood-based biomarker research examining why responses to an Alzheimer’s antibody vary, previewing an article that maps divergent biological signals and testing approaches.
Key Takeaways
- Researchers measured 130 plasma proteins from 1,967 participants across 2,385 samples using an ultra-sensitive panel.
- Proteins associated with amyloid clearance differed largely from proteins linked to later cognitive decline.
- Brain-derived tau measures outperformed peripheral tau at distinguishing treated patients from controls at multiple timepoints.
